MindMaze Theraputics
+ Menu
  • Solutions
    • MindMaze platform
      • Our approach
      • Clinical evidence
    • Therapy & monitoring
      • Companion
      • MindMotion GO
      • MindPod
      • Izar
      • Physilog
      • ToapRun
    • Drug development
      • Relief Therapeutics pipeline and portfolio
  • Research & Innovation
    • MindMaze Labs
      • Neurotherapeutics frontiers
      • Research collaborations
      • Human performance
      • Deep technology
  • Investor relations
    • Share price
    • Board & executive team
    • Key stock information
    • Financial reports
    • Articles of association
    • US ADR Program
    • Financial calendar
    • News and Events
    • Shareholder’s general meeting
    • Equity research coverage
    • Investor presentations
    • Investor newsletter
  • About
    • MindMaze Therapeutics
    • Media
    • Careers
    • Testimonials
    • Contact
MindMaze Theralputics
+ Menu
  • Solutions
    • MindMaze platform
      • Our approach
      • Clinical evidence
    • Therapy & monitoring
      • Companion
      • MindMotion GO
      • MindPod
      • Izar
      • Physilog
      • ToapRun
    • Drug development
      • Relief Therapeutics pipeline and portfolio
  • Research & Innovation
    • MindMaze Labs
      • Neurotherapeutics frontiers
      • Research collaborations
      • Human performance
      • Deep technology
  • Investor relations
    • Share price
    • Board & executive team
    • Key stock information
    • Financial reports
    • Articles of association
    • US ADR Program
    • Financial calendar
    • News and Events
    • Shareholder’s general meeting
    • Equity research coverage
    • Investor presentations
    • Investor newsletter
  • About
    • MindMaze Therapeutics
    • Media
    • Careers
    • Testimonials
    • Contact
Investor relations

MindMaze Therapeutics investor relations

Select which section you would like to explore:

Share price
Board & executive team
Key stock information
Financial reports
Articles of association
US ADR Program
Financial calendar
News and events
Shareholder’s general meeting
Equity research coverage
Investor presentations
Investor newsletter

Chemin de Roseneck 5
1006 Lausanne, Switzerland

+41 21 552 08 01
info@mindmaze.com
  • MindMaze platform
  • Therapy & monitoring
  • Drug development
  • Research & innovation
  • Investor relations
  • About
  • Contact
copyright © 2025 | terms and conditions | EU privacy policy | U.S. privacy policy | PERSONAL DATA REQUESTS
We value your privacy
We use cookies to enhance your browsing experience and analyze our traffic. By clicking "I accept", you consent to our use of cookies.